Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482486 | 0.89 | CYP1A2 (0.47) | OR51E2CYP1A2FKBP5CRBNHTT | |
| SCHEMBL5502631 | 0.89 | CYP1A2 (0.37) | CHRNA7CYP1A2OPRL1OPRM1NOS3 | |
| SCHEMBL9766490 | 0.86 | CYP1A2 (0.49) | CYP1A2HTTCCR2ALDH1A1 | |
| SCHEMBL2526110 | 0.85 | HTT (0.41) | OR51E2FKBP5CRBNHTTCCR2 | |
| SCHEMBL5014640 | 0.83 | OR51E2 (0.37) | OR51E2FKBP5CRBNOPRL1 | |
| SCHEMBL28731850 | 0.79 | SIGMAR1 (0.40) | OR51E2CYP1A2FKBP5CRBN | |
| SCHEMBL27924745 | 0.79 | OR51E2 (0.33) | OR51E2CYP1A2FKBP5CRBN | |
| SCHEMBL26718370 | 0.78 | CYP1A2 (0.46) | CYP1A2HTTCCR2OPRL1ALDH1A1 | |
| SCHEMBL1567651 | 0.76 | CYP1A2 (0.53) | CYP1A2CCR2ALDH1A1 | |
| SCHEMBL1777044 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012963-A1 | POLYMERIZABLE FATTY ACID-DERIVATIVE-MONOMERS WITH TERMINAL OLEFINIC DOUBLE BONDS, POLYMERS CONTAINING SAME MONOMERS, PRODUCTION AND USE THEREOF | BASF SE (DE) | 2017-01-26 | — | — | WO | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | claimed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| US-20080182773-A1 | Thickeners Based on Polymers Comprising Amine Groups | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-31 | — | — | US | claimed |
| EP-1863574-A1 | THICKENER BASED ON AMINE GROUP-CONTAINING POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2007-12-12 | — | — | EP | claimed |
| WO-2006100299-A1 | THICKENER BASED ON AMINE GROUP-CONTAINING POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-28 | — | — | WO | claimed |
| CN-120157874-A | High-elasticity light nylon elastomer and hydrolytic polymerization preparation method thereof | 浙江恒逸石化研究院有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-2170964-B1 | HIGH-CATION COPOLYMERS BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS | BASF SE (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-8623343-B2 | Highly cationic copolymers based on quaternized nitrogen-containing monomers | BASF SE (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130108959-A1 | USE OF A COMPOSITION COMPRISING VINYL MONOMER-COMPRISING POLYMER, SOLVENT AND AT LEAST ONE HALOGEN-FREE BIOCIDE | BASF SE (DE) | 2013-05-02 | — | — | US | disclosed |
| US-20120118446-A1 | AQUEOUS METAL QUENCHING MEDIUM | BASF SE (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2376550-A1 | MODIFIED POLYVINYLLACTAMS | BASF SE (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20030036659-A1 | Method for the production of n-alkenyl amides | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-20 | — | — | US | disclosed |
| US-20030028035-A1 | Method for producing n-alkenyl amides | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-06 | — | — | US | disclosed |
| EP-1240140-A1 | METHOD FOR THE PRODUCTION OF N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-18 | — | — | EP | disclosed |
| EP-1240139-A1 | METHOD FOR PRODUCING N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046139-A1 | METHOD FOR PRODUCING N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001046141-A1 | METHOD FOR THE PRODUCTION OF N-ALKENYL AMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | CHRNA7 23/4885OR51E2 983/4885CYP1A2 175/4885 |
| US-20030036659-A1 | Method for the production of n-alkenyl amides | NAT1, SAT1, AGPAT2 | CHRNA7 1118/4885OR51E2 2990/4885CYP1A2 184/4885 |
| US-20030028035-A1 | Method for producing n-alkenyl amides | NAT1, H1-2, H1-0 | CHRNA7 760/4885OR51E2 1638/4885CYP1A2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.